# Study of Aztreonam for Inhalation in Children With Cystic Fibrosis and New Infection of the Airways by Pseudomonas Aeruginosa Bacteria

> **NCT03219164** · PHASE3 · TERMINATED · sponsor: **Gilead Sciences** · enrollment: 149 (actual)

## Conditions studied

- Pseudomonas Aeruginosa Respiratory Tract Infection/Colonization
- Cystic Fibrosis

## Interventions

- **DRUG:** AZLI
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03219164
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-11-28
- **Primary completion:** 2020-05-27
- **Final completion:** 2021-09-23
- **Target enrollment:** 149 (ACTUAL)
- **Why stopped:** Study was terminated early by sponsor due to the challenges and risks introduced by Coronavirus disease 2019 (COVID-19) pandemic.
- **Last updated:** 2022-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03219164

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03219164, "Study of Aztreonam for Inhalation in Children With Cystic Fibrosis and New Infection of the Airways by Pseudomonas Aeruginosa Bacteria". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03219164. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*